Generic Wegovy is here: Sevmia approved in Canada
On June 29, 2026, Health Canada approved Sevmia (Apotex) — the first generic version of Wegovy (semaglutide) for chronic weight management, and the first generic semaglutide approved for weight loss in Canada. Here's what Sevmia is, who it's for, what it's likely to cost, and how it fits the wider generic semaglutide rollout.
Last updated: June 30, 2026
Latest update · June 30, 2026
Health Canada approved Sevmia (Apotex) on June 29, 2026 — the first generic Wegovy and the first generic semaglutide cleared for weight management in Canada. Read the Health Canada announcement → Pricing has not been published yet — see the outlook below.
Approval timeline
Based on publicly available Health Canada filings and regulatory timelines.
October 30, 2025
Dr. Reddy’s Laboratories received a Notice of Non-Compliance from Health Canada on its initial generic semaglutide submission (resolved — see April 28, 2026).
December 22, 2025
Health Canada approved Plosbrio and Poviztra, Novo Nordisk’s lower-cost authorized brands of Ozempic and Wegovy respectively, ahead of the expected generic wave.
January 4, 2026
Novo Nordisk’s semaglutide data exclusivity expired in Canada, opening the regulatory pathway for generic manufacturers.
January 2026
Seven generic semaglutide submissions under Health Canada review from Sandoz Canada, Apotex (three submissions), Taro Pharmaceuticals, Aspen Pharmacare, and Teva Canada.
February 2, 2026
PharmaTher announced a strategic initiative to pursue Health Canada approval for generic semaglutide, targeting broad dose coverage from 0.25 mg to 2.4 mg.
April 28, 2026
Dr. Reddy’s Laboratories approved — first generic semaglutide approved by Health Canada. Type 2 diabetes indication only (equivalent to generic Ozempic). Dr. Reddy’s resolved its October 2025 Notice of Non-Compliance in approximately six months.
May 1, 2026
Apotex approved — Health Canada approved Apo-Semaglutide Injection, the second generic semaglutide product authorized in Canada. Type 2 diabetes indication only.
June 29, 2026
Sevmia (Apotex) approved — the first generic semaglutide authorized by Health Canada for chronic weight management, and the first generic referencing Wegovy (rather than Ozempic). Developed by Apotex with Orbicular Pharmaceutical Technologies. The two earlier 2026 approvals reference Ozempic and cover the Type 2 diabetes indication only; Sevmia is the first generic approved for weight management. Most news outlets reported the name as “Svemia,” a transposition — Apotex and Health Canada spell it “Sevmia.”
Through 2026
Six additional generic semaglutide submissions remain under Health Canada review. Further decisions expected in the coming weeks and months; manufacturer production scale-up and pharmacy availability typically lag approval by weeks to months.
Timeline is based on public information only. GLP1Prices does not have advance knowledge of Health Canada decisions.
What the price drop will actually look like
Canada's generic drug pricing framework — the pan-Canadian Tiered Pricing Framework, administered through the pan-Canadian Pharmaceutical Alliance — caps generic prices in steps as more manufacturers enter a market, with an automatic step-down built in even at the single-generic stage.
Using the current manufacturer list price for Ozempic of approximately $228 for a four-week supply (the official “brand reference price,” before pharmacy and distributor markups), the framework caps generic prices as follows:
| Stage | Generic price cap | Reduction from brand list |
|---|---|---|
| 1 generic, first 3 months | 75% of brand (~$171) | ~25% off |
| 1 generic, after 3 months | 55% of brand (~$125) | ~45% off |
| 2 generics | 50% of brand (~$114) | ~50% off |
| 3 or more generics (injectables) | 35% of brand (~$80) | ~65% off |
These are list-price caps for public drug plan formularies. Retail prices include pharmacy dispensing fees and markups, so absolute dollar figures at the counter will be higher than the table — but percentage reductions track proportionally.
With three generic semaglutide products now approved (the latest, Sevmia, on June 29, 2026) and pharmacy price comparison showing launches just beginning, the realistic near-term consumer price reduction lands in the 25–50% range depending on which generics are actively dispensing in your province. What the 65% number actually means — the floor reached only after three or more manufacturers are simultaneously on market.
Generic Wegovy in Canada: what Sevmia is
On June 29, 2026, Health Canada authorized Sevmia — a generic semaglutide made by Apotex (developed with Orbicular Pharmaceutical Technologies). It is the first generic version of Wegovy and the first generic semaglutide approved in Canada for chronic weight management. Sevmia references Wegovy (Novo Nordisk) as its brand comparator. (Most news outlets reported the product as “Svemia” — a transposition; Apotex and Health Canada spell it Sevmia.)
Health Canada authorized Sevmia for chronic weight management in patients aged 12 and older — as an adjunct to a reduced-calorie diet and increased physical activity — for adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, and to reduce the risk of a non-fatal heart attack in adults with established cardiovascular disease and a BMI ≥ 27. Sevmia is a once-weekly injection; follow the dosing set out in the official Sevmia product monograph and confirm with your prescriber or pharmacist.
Sevmia is the third generic semaglutide cleared in Canada — but the first for weight loss. The earlier two (Dr. Reddy's, April 28, 2026; Apotex's Apo-Semaglutide Injection, May 1, 2026) reference Ozempic and cover the Type 2 diabetes indication only. Health Canada is reviewing six other generic semaglutide submissions, with more decisions expected in the coming weeks and months.
What will Sevmia cost? (pricing pending)
No Sevmia price has been published yet. Health Canada notes that generic medicines are typically 45–90% cheaper than the brand once competition builds, so generic Wegovy pricing should land well below brand Wegovy over time — but the exact launch price, provinces, and pharmacies are not yet confirmed. We'll update this page with verified Sevmia prices the moment they are announced. The tiered-pricing framework above shows how those reductions typically phase in as more manufacturers enter the market.
Availability & pricing pending — check back, or join the free alert to be notified when Sevmia prices go live.
If your prescription is written for Wegovy, ask your pharmacist or prescriber whether a generic substitution with Sevmia is available once it is stocked in your province. Telehealth providers in Canada can also confirm which brand your prescription is written for if you're unsure.
Sources
- Health Canada — Canada approves first generic semaglutide for weight loss
- Apotex press release (PR Newswire) — Health Canada approval for Sevmia
- CBC — Apotex generic Wegovy approval
- CTV News — Health Canada approves first generic semaglutide for weight loss
- Global News — Canada semaglutide injection for weight loss
New approvals are clearing. Don't miss the next one.
Get notified when additional generic semaglutide products are approved and prices are listed in Canada.
Track generic semaglutide prices at Canadian pharmacies
Apo-Semaglutide launched in May 2026. Get notified when it's available at your pharmacy or when prices change.
What you'll receive
- Email notification when additional generic semaglutide prices are listed
- Price comparison across Canadian pharmacies — in your province
- No spam — one email when prices are live, unsubscribe any time